Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Budesonide for Low-grade Duodenal Inflammation in Functional Dyspepsia
2024-517035-43-00Phase 4Authorised
- Sponsor
- UZ Leuven
- Start
- Oct 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of budesonide in functional dyspepsia (FD), sponsored by UZ Leuven. Primary endpoint: Change in duodenal eosinophils after 8 weeks of treatment. Planned start Oct 2024; status: authorised.
02
Drugs
budesonide
03
Conditions
functional dyspepsia (FD)
Beyond the preview
Go deeper on 2024-517035-43-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517035-43-00.